Non-small cell lung cancer metastatic Trials in Disease

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

This trial compares a new treatment combination of acasunlimab with pembrolizumab against the standard treatment docetaxel for patients who have already received PD-1/PD-L1 inhibitors and platinum-based chemotherapy. The study focuses on evaluating whether this new combination can improve overall survival compared to docetaxel alone.

Main inclusion criteria: Patients must have metastatic NSCLC with positive PD-L1 expression, previously treated with PD-1/PD-L1 inhibitors and platinum-based chemotherapy, with measurable disease and adequate organ function.

Main exclusion criteria: Patients with different cancer types or who have received more than one prior chemotherapy treatment are excluded.

Study goal: To determine if acasunlimab combined with pembrolizumab improves survival compared to docetaxel in previously treated patients.

Investigational drugs: Acasunlimab (GEN1046) combined with pembrolizumab is being tested against docetaxel, a standard chemotherapy drug.

Study Comparing Ivonescimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Squamous Non-Small Cell Lung Cancer

This study evaluates whether ivonescimab combined with chemotherapy offers better outcomes than pembrolizumab with chemotherapy for patients with squamous NSCLC. The trial measures overall survival and other treatment responses.

Main inclusion criteria: Patients must have metastatic squamous NSCLC with PD-L1 expression, no prior systemic treatment for metastatic disease, adequate organ function, and ECOG score of 0 or 1.

Main exclusion criteria: Patients with other cancer types, those who have received prior treatments, or with serious medical conditions are excluded.

Study goal: To determine if ivonescimab plus chemotherapy improves overall survival compared to pembrolizumab plus chemotherapy.

Investigational drugs: Ivonescimab (AK112/SMT112) is tested alongside carboplatin and paclitaxel, compared to pembrolizumab with the same chemotherapy agents.

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

This trial investigates whether adding MK-2870 to pembrolizumab improves survival in patients with high PD-L1 expression who have not received prior systemic treatment for metastatic NSCLC.

Main inclusion criteria: Patients must have NSCLC with PD-L1 TPS of 50% or higher, no prior systemic treatment, measurable disease, ECOG performance status 0 or 1, and life expectancy of at least 3 months.

Main exclusion criteria: Patients without EGFR mutations or those requiring specific targeted therapies are excluded.

Study goal: To assess whether MK-2870 combined with pembrolizumab improves overall survival and progression-free survival compared to pembrolizumab alone.

Investigational drugs: MK-2870 combined with pembrolizumab is being tested to enhance immune response against cancer cells.

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

This study compares ONC-392, a humanised IgG1 monoclonal antibody, with docetaxel chemotherapy for patients whose cancer progressed after PD-1/PD-L1 inhibitor treatment.

Main inclusion criteria: Patients must have metastatic NSCLC with progression after at least 12 weeks of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy, at least one measurable tumor, ECOG score 0 or 1, adequate organ function, and life expectancy of at least 3 months.

Main exclusion criteria: Patients without documented progression after PD-1/PD-L1 treatment or not within the specified criteria are excluded.

Study goal: To determine whether ONC-392 improves overall survival compared to docetaxel in patients with disease progression after immunotherapy.

Investigational drugs: ONC-392 is compared to docetaxel, a standard chemotherapy agent for second-line treatment.

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

This trial evaluates whether adding sacituzumab govitecan to pembrolizumab improves outcomes for patients with high PD-L1 expression who have not received prior treatment for metastatic NSCLC.

Main inclusion criteria: Patients must have metastatic NSCLC with PD-L1 TPS of 50% or more, no prior systemic treatment, adequate organ function, and life expectancy of at least 3 months.

Main exclusion criteria: Patients with other cancer types or who have received recent cancer treatments are excluded.

Study goal: To assess whether pembrolizumab plus sacituzumab govitecan improves progression-free survival and overall survival compared to pembrolizumab alone.

Investigational drugs: Sacituzumab govitecan, an antibody-drug conjugate, is tested in combination with pembrolizumab.

Study Comparing Subcutaneous Pembrolizumab with Hyaluronidase to Intravenous Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1

This study compares the pharmacokinetics and safety of subcutaneous pembrolizumab (MK-3475A) with hyaluronidase versus intravenous pembrolizumab for first-line treatment of patients with PD-L1 TPS ≥50%.

Main inclusion criteria: Patients must have NSCLC confirmed by histology or cytology, measurable disease, tumor tissue sample available, and life expectancy of at least 3 months.

Main exclusion criteria: Patients who have received prior systemic treatment or have serious medical conditions are excluded.

Study goal: To evaluate if subcutaneous administration of pembrolizumab offers similar efficacy and safety to intravenous administration.

Investigational drugs: MK-3475A (subcutaneous pembrolizumab with hyaluronidase) is compared to intravenous pembrolizumab.

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

This trial evaluates volrustomig (MEDI5752) combined with chemotherapy against pembrolizumab plus chemotherapy for patients with PD-L1 expression less than 1%.

Main inclusion criteria: Patients must have metastatic NSCLC with PD-L1 less than 50%, no prior systemic treatment, adequate organ function, and ECOG performance status 0 or 1.

Main exclusion criteria: Patients with PD-L1 levels of 1% or higher or who have received prior treatments are excluded.

Study goal: To determine whether volrustomig plus chemotherapy improves progression-free survival and overall survival compared to pembrolizumab plus chemotherapy.

Investigational drugs: Volrustomig combined with platinum-based chemotherapy and pemetrexed is tested against pembrolizumab with the same chemotherapy.

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study investigates the combination of ABBV-400 and budigalimab for patients with advanced non-squamous NSCLC who have not received prior systemic treatment and have no actionable genomic alterations.

Main inclusion criteria: Patients must have advanced NSCLC without prior systemic treatment, no actionable genomic alterations, adequate organ function, ECOG status 0-1, and life expectancy over 12 weeks.

Main exclusion criteria: Patients with other cancer types, serious medical conditions, or recent major surgery are excluded.

Study goal: To assess the safety and effectiveness of ABBV-400 combined with budigalimab in first-line treatment.

Investigational drugs: ABBV-400 combined with budigalimab is being tested as a novel immunotherapy approach.

Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

This trial evaluates two dosing regimens of adagrasib for patients with KRAS G12C-mutated NSCLC who have progressed after platinum-based chemotherapy and immune checkpoint inhibitor therapy.

Main inclusion criteria: Patients must have advanced NSCLC with KRAS G12C mutation, previous treatment with platinum chemotherapy and immune checkpoint inhibitor, adequate organ function, ECOG status 0-1, and life expectancy over 3 months.

Main exclusion criteria: Patients without KRAS G12C mutation or who have not received prior required treatments are excluded.

Study goal: To determine which dosing regimen of adagrasib is more effective and better tolerated for treating KRAS G12C-mutated NSCLC.

Investigational drugs: Adagrasib (MRTX849) is tested in two different dosing regimens (600 mg twice daily without food versus 400 mg twice daily with food).

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This study evaluates whether adding adagrasib to pembrolizumab and chemotherapy improves outcomes for patients with KRAS G12C-mutated NSCLC who have not received prior treatment for advanced disease.

Main inclusion criteria: Patients must have advanced NSCLC with KRAS G12C mutation, no prior systemic treatment, measurable disease on CT or MRI, ECOG status 0 or 1, and adequate organ function.

Main exclusion criteria: Patients who have received prior treatment for advanced cancer or belong to vulnerable populations are excluded.

Study goal: To assess whether adagrasib combined with pembrolizumab and chemotherapy improves progression-free survival and overall survival.

Investigational drugs: Adagrasib is tested in combination with pembrolizumab and platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed.

Summary

The clinical trials for metastatic non-small cell lung cancer reflect a diverse range of treatment strategies, with significant concentration in European countries including Germany, Poland, Spain, France, and Italy. Many studies focus on combining immunotherapies such as pembrolizumab with novel agents or chemotherapy regimens. Several trials specifically target genetic mutations like KRAS G12C and EGFR alterations, representing personalized medicine approaches. The research includes evaluation of both new drug combinations and novel administration routes (such as subcutaneous versus intravenous). Most trials are in Phase 2 or 3, indicating advanced stages of development with potential for near-term clinical application. The high number of trials across multiple countries demonstrates the significant medical need and active research efforts to improve treatment outcomes for this challenging disease.